The National Cheng Kung University Hospital is a hospital in North District, Tainan, Taiwan.

There are 1,342 beds in National Cheng Kung University Hospital.

During the past decade, National Cheng Kung University Hospital conducted 437 clinical trials. In the 10-year time frame, 437 clinical trials started and 123 clinical trials were completed, i.e. on average, 28.1% percent of trials that started reached the finish line to date. In the past 5 years, 239 clinical trials started and 92 clinical trials were completed. i.e. 38.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Cheng Kung University Hospital" #1 sponsor was "National Cheng-Kung University Hospital" with 98 trials, followed by "Pfizer" with 38 trials sponsored, "Janssen Research & Development, LLC" with 27 trials sponsored, "Eli Lilly and Company" with 26 trials sponsored and "National Health Research Institutes, Taiwan" with 26 trials sponsored. Other sponsors include 341 different institutions and companies that sponsored additional 151 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Cheng Kung University Hospital" #1 collaborator was "National Cheng-Kung University Hospital" with 28 trials as a collaborator, "National Taiwan University Hospital" with 21 trials as a collaborator, "Taipei Veterans General Hospital, Taiwan" with 18 trials as a collaborator, "Chang Gung Memorial Hospital" with 16 trials as a collaborator and "China Medical University Hospital" with 16 trials as a collaborator. Other collaborators include 264 different institutions and companies that were collaborators in the rest 151 trials.

According to Clinical.Site data, the most researched conditions in "National Cheng Kung University Hospital" are "Hepatocellular Carcinoma" (17 trials), "Gastric Cancer" (13 trials), "Non-Small Cell Lung Cancer" (12 trials), "Carcinoma, Non-Small-Cell Lung" (11 trials) and "Breast Cancer" (10 trials). Many other conditions were trialed in "National Cheng Kung University Hospital" in a lesser frequency.

Most popular intervention types in "National Cheng Kung University Hospital" are "Drug" (438 trials), "Other" (55 trials), "Biological" (47 trials), "Device" (23 trials) and "Procedure" (18 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (101 trials), "Pembrolizumab" (22 trials), "Cisplatin" (18 trials), "Carboplatin" (15 trials) and "Docetaxel" (13 trials). Other intervention names were less common.

The vast majority of trials in "National Cheng Kung University Hospital" are 529 trials for "All" genders, 17 trials for "Female" genders and 15 trials for "Male" genders.

Currently, there are 244 active trials in "National Cheng Kung University Hospital". 6 are not yet recruiting, 134 are recruiting, 98 are Active, not recruiting, and 6 are Enrolling by invitation. In total, there were 210 completed trials in National Cheng Kung University Hospital, undefined suspended trials, and 53 terminated clinical trials to date.

Out of the total trials that were conducted in National Cheng Kung University Hospital, 87 "Phase 1" clinical trials were conducted, 136 "Phase 2" clinical trials and 218 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 34 trials, and there were also 62 trials that are defined as “Not Applicable".